Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: A systematic review and meta-analysis of randomised controlled trials

Annals of the Rheumatic Diseases

Volumn 73, Issue 2, 2014, Pages 414-419

  Goulabchand, Radjiv ^a   Mouterde, Gaël ^a   Barnetche, Thomas ^b   Lukas, Cédric ^a   Morel, Jacques ^a   Combe, Bernard ^a  

^a LAPEYRONIE HOSPITAL   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; JOINT RADIOGRAPHY; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SYSTEMATIC REVIEW;

EID: 84891744277     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202641     Document Type: Article

References (27)

1. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2): ii14-17. (Pubitemid 40288513)
2. Gladman DD, Thavaneswaran A, Chandran V, et al. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis 2011;70:2152-4.
3. Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003;42:1460-8. (Pubitemid 37508919)
4. Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868-72. (Pubitemid 27452539)
5. Gladman DD, Farewell VT, Wong K, et al. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41:1103-10. (Pubitemid 28265412)
6. Mease P. TNFá therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004;63:755-8. (Pubitemid 38850443)
7. Partsch G, Wagner E, Leeb B, et al. T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis 1998;57:691-3. (Pubitemid 28558975)
8. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319-26.
9. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of MTX in PsA. Rheumatology. (Oxford) 2012;51:1368-77.
10. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
11. Klareskog L, Van Der Heijde D, De Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81. (Pubitemid 38296553)
12. Fagerli KM, Lie E, Van Der Heijde D, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study Ann Rheum Dis 2014;73:132-7.
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12. (Pubitemid 26120810)
14. Van Der Heijde D, Sharp J, Wassenberg S, et al. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 2005;64(Suppl 2): ii61-4. (Pubitemid 40288525)
15. Van Der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3. (Pubitemid 30058662)
16. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21.
17. Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476-88.
18. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9.
19. Van Der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007;56:2698-707. (Pubitemid 47237288)
20. Kavanaugh A, Van Der Heijde D, McInnes I, et al. Golimumab, a human TNF-alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: clinical efficacy, radiographic, and safety findings through 1 year of the randomized, placebo-controlled, GO-REVEAL® study. Arthritis Rheum 2012;64:2504-17.
21. Wassenberg S, Fischer-Kahle V, Herborn G, et al. A method to score radiographic change in psoriatic arthritis. Z Rheumatol 2001;60:156-66. (Pubitemid 32651715)
22. Bruynesteyn K, Boers M, Kostense P, et al. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 2005;64:179-82. (Pubitemid 40193607)
23. Gladman DD, Mease PJ, Choy E H S, et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 2010;12:R113.
24. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. (Pubitemid 44205029)
25. Gladman DD, Fleischmann RM, Coteur G, et al. Effect of Certolizumab Pegol on the multiple facets of Psoriatic Arthritis as reported by patients: 24 week patient Reported Outcome Results of a Phase 3 Double Blind Randomized Placebocontrolled study. ACR 2012 abstract supplement 2012;4:S242.
26. Visser K, Goekoop-Ruiterman Y P M, De Vries-Bouwstra JK, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 2010;69:1333-7.
27. Morel J, Combe B. How to predict prognosis in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19:137-46. (Pubitemid 40003945)